Recently, according to Fierce Biotech, BD Medical officially announced the appointment of Bilal Muhsin as executive vice president, and he will serve as president of the "Connected Care" department, one of the four major departments of BD Medical. The appointment will take effect immediately from the date of official announcement.

It is reported that Bilal Muhsin is a veteran of Masimo, who has been in the company for 25 years and served as executive vice president of engineering, marketing and regulatory affairs. Founded in 1989, Masimo is a globally recognized leader in non-invasive monitoring technology, dedicated to developing and producing various leading monitoring technologies and equipment in the medical industry, including meters, sensors, pulse oximeters, patient monitors and automation equipment.

After joining BD Medical, Bilal Mushin will lead strategic development, report to Tom Polen, chairman, CEO and president of BD, and participate in the decision-making of BD's global executive leadership team as a core member.

Tom Polen has high hopes for the new helmsman. He said that Bilal has extensive and deep knowledge in connected care technology, software and informatics strategy, and his extreme focus on customers will have a profound impact on BD. BD Medical will advance our connected care strategy through cutting-edge, AI-driven technology to change patient care by improving safety, efficiency and treatment effectiveness.

He also emphasized that the new personnel appointment is also to implement the "New BD" strategy, and this appointment is also another step on the road to becoming a differentiated pure medical technology leader. Bilal will play a key role in helping BD leverage its significant advantages in digitalization, robotics and artificial intelligence technology innovation to accelerate BD Medical's growth and impact on healthcare.

It is worth noting that on February 5 this year, BD Medical officially announced the news of the spin-off of its business, officially deciding to divest its bioscience and diagnostic solutions business, which is valued at approximately US$30 billion. After the adjustment, the business of the new BD Medical will become a pure medical device company, and its business segments are divided into 4 items:

medical necessities (consumables such as infusion and blood collection, with annual shipments exceeding 10 billion pieces and stable cash flow);

connected care (smart pharmacies, patient monitoring, AI and automation drive efficiency improvement);

biopharmaceutical systems (biological drug injection equipment, benefiting from the explosion of demand for self-injection therapies such as GLP-1);

interventional treatment (innovative solutions for chronic diseases such as urology, peripheral vascular, and tumors).

In the future, the new BD Medical will rely on the basic plate of medical consumables and extend to high value-added fields (such as GLP-1 drug supporting equipment and AI pharmacies), aiming to become a "benchmark for medical technology innovation." In addition, the "new BD" strategy also plans to make more complementary acquisitions along these directions. BD Medical first launched its "BD 2025" plan in 2020, with the goal of achieving annual revenue growth of 5.5% or higher.

The spun-off life science business will independently operate the life science tools and diagnostics business, focusing on high-growth areas such as flow cytometry, microbial testing, and molecular diagnostics. In the future, it will benefit from the demand for precision medicine and infectious disease testing, and its technological barriers (such as flow cytometers and molecular diagnostics) will support high gross profit growth.

https://news.yaozh.com/archive/45771.html